These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11583143)

  • 1. Pharmacology of cardiovascular chronotherapeutic agents.
    Smith DH
    Am J Hypertens; 2001 Sep; 14(9 Pt 2):296S-301S. PubMed ID: 11583143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning.
    Smith DH; Neutel JM; Weber MA
    Am J Hypertens; 2001 Jan; 14(1):14-9. PubMed ID: 11206672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study.
    Portaluppi F; Smolensky MH
    Chronobiol Int; 2010 Sep; 27(8):1652-67. PubMed ID: 20854140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product.
    White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD
    Am J Cardiol; 1998 Feb; 81(4):424-31. PubMed ID: 9485131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product.
    White WB; Lacourciere Y; Gana T; Pascual MG; Smith DH; Albert KS
    Am Heart J; 2004 Oct; 148(4):628-34. PubMed ID: 15459593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease.
    Smolensky MH; Portaluppi F
    Am Heart J; 1999 Apr; 137(4 Pt 2):S14-S24. PubMed ID: 10097242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension.
    White WB; Johnson MF; Black HR; Fakouhi TD
    Ethn Dis; 1999; 9(3):341-9. PubMed ID: 10600056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chronotherapeutic approach to the management of hypertension.
    White WB
    Am J Hypertens; 1996 Apr; 9(4 Pt 3):29S-33S. PubMed ID: 8722414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.
    Hermida RC
    Chronobiol Int; 2007; 24(4):749-75. PubMed ID: 17701685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes.
    Bakris G; Sica D; Ram V; Fagan T; Vaitkus PT; Anders RJ
    Am J Hypertens; 2002 Jan; 15(1 Pt 1):53-7. PubMed ID: 11824861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose- and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; López JE; Rodríguez M; Chayán L; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2007; 24(3):471-93. PubMed ID: 17612946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation.
    Sica D; Frishman WH; Manowitz N
    Heart Dis; 2003; 5(3):176-81. PubMed ID: 12783630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension.
    White WB
    Am J Hypertens; 1999 Feb; 12(2 Pt 2):50S-55S. PubMed ID: 10090295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil.
    Prisant LM; Black HR; Messerli F; Weber M
    Am J Ther; 2002; 9(6):476-83. PubMed ID: 12424503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
    Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR
    Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronotherapeutics: a surge of ideas.
    Prisant LM
    Clin Cornerstone; 2004; 6(4):7-17. PubMed ID: 15850762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.
    Hermida RC; Ayala DE; Smolensky MH; Fernández JR; Mojón A; Portaluppi F
    Hypertens Res; 2016 May; 39(5):277-92. PubMed ID: 26657008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project.
    Hermida RC
    Chronobiol Int; 2016; 33(7):906-36. PubMed ID: 27221952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.